Alzheimer's disease resident survival guide
Alzheimer's disease Resident Survival Guide Microchapters |
---|
Overview |
Causes |
Diagnosis |
Treatment |
Do's |
Don'ts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Moises Romo M.D.
Synonyms and keywords:Alzheimer's disease management, Alzheimer's disease workup, Alzheimer's disease approach, approach to Alzheimer's disease, Alzheimer's disease treatment
Overview
Alzheimer's disease is the most common cause of dementia among older people. Dementia is a loss of thinking, remembering, and reasoning skills that interfere with a person's daily life and activities. The diagnosis of Alzheimer's disease (AD) is made on the basis of clinical criteria described by either the National Institute on Aging and the Alzheimer's Association (NIA-AA) or DSM-V (Diagnostic and Statistical Manual of Mental Disorders, fifth edition). There is no known cure for Alzheimer's disease (AD). Available treatments offer relatively small symptomatic benefit but remain palliative in nature. Current treatments can be divided into pharmacological, psychosocial, and caregiving.
Causes
Life-Threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Alzheimer's disease is not a life-threatening condition that may result in death or permanent disability within 24 hours if left untreated.
Common Causes
While there is no direct cause for the development of Alzheimer's disease, there are several factors that may contribute to its acquisition:
- Chromosomal
- Down syndrome
- Trisomy 21
- Overexpression of amyloid precursor protein (APP) on chromosome 21
- Develop the neuropathologic hallmarks of AD after 40 years of age
- Down syndrome
- Familial
- Unknown (includes genetic/environment interactions)
- Multifactorial
- Aging
- Genetic predisposition
- Exposure to one or more environmental agents including head trauma, low level of education, viruses, and/or toxins
- Multifactorial
Diagnosis
Shown below is an algorithm summarizing the diagnosis of amnesia according to the the American Academy of Neurology guidelines:[1]
Treatment
Shown below is an algorithm summarizing the treatment of Alzheimer's disease according to the American Academy of Neurology guidelines:[2]
Patient with diagnosed Alzheimer's disease | |||||||||||||||||||||||||||||||||||||||||
Mild to moderate | Moderate to severe | ||||||||||||||||||||||||||||||||||||||||
Initiate therapy •Donepezil. 5 mg once daily; titrate 10 mg once daily •Galantamine (solution). 4 mg twice daily; titrate to 8 mg twice daily •Galantamine (ER capsules). 8 mg once daily; titrate to 16 mg once daily •Rivastigmine (patch). 4.6 mg once daily; titrate to 9.5 mg once daily •Rivastigmine (oral). 1.5 mg twice daily; titrate to 6 mg twice daily | |||||||||||||||||||||||||||||||||||||||||
Adverse event Consider switch to a different ChEI | Disease progression Consider high dose or switch to a different ChEI | Initiate therapy •Donepezil. 5 mg once daily; titrate 10 mg once daily •Rivastigmine (patch). 4.6 mg once daily; titrate to 9.5 mg once daily •Memantine. 5 mg once daily; titrate to 10 mg twice daily or Memantine XR. 7 mg once daily; titrate to 28 mg once daily •Combination ChEI+ Memantine. 7 mg twice daily or 10 mg once daily (ER); titrate to 10 mg twice daily or 28 mg once daily (ER) | |||||||||||||||||||||||||||||||||||||||
Monitor and reevaluate therapy Monitor every 3-4 months and titrate dose as needed | |||||||||||||||||||||||||||||||||||||||||
Adverse event Consider switch to a different therapy | Disease progression Consider higher dose or switch to a different therapy | ||||||||||||||||||||||||||||||||||||||||
Discontinue therapy When all cognitive function and functional abilities are lost at terminal stages of AD | |||||||||||||||||||||||||||||||||||||||||
Recommendations for maintaining brain health in elderly patients with and without Alzheimer's Disease |
---|
|
|
Dos
- Perform laboratory testing to exclude potentially reversible causes of amnesia. Initial tests should include a CBC, urine toxicology, thyroid function, folate, and vitamin B12 level.
- When performing cognitive assessment, use tests such as MMSE, Mini-cog, MoCA, SIB-8, and AD8.[3][4][5][6]
- When determining level of independence and level of disability, use test such as ADCS–ADL.[7]
- When determining the level of behavioral symptoms, use the NPI-Q test.[8]
- Identify primary caregiver and assess their health, as well as adequacy of family and other support systems.[9]
- Neuroimaging may diagnose vascular disease, normal pressure hydrocephalus, tumors, abscess.[10]
- Perform a minimental status test on physical examination and pay special attention to concentration domain. Minimental testing has the potential to distinguish mild cognitive impairment from dementia.[11]
- Always have in mind depression as a possible cause of memory impairment. Depression is common cause of amnesia; a SIGE CAPS evaluation may disclose an underlying mood disorder.[12].
Don'ts
- If alcoholism and thiamine deficiency is suspected, do not administer glucose before thiamine. Administration of glucose before thiamine may lead to Wernicke encephalopathy.[13]
References
- ↑ Jahn H (December 2013). "Memory loss in Alzheimer's disease". Dialogues Clin Neurosci. 15 (4): 445–54. PMC 3898682. PMID 24459411.
- ↑ Grossberg, George T.; Tong, Gary; Burke, Anna D.; Tariot, Pierre N.; Fink, Anne (2019). "Present Algorithms and Future Treatments for Alzheimer's Disease". Journal of Alzheimer's Disease. 67 (4): 1157–1171. doi:10.3233/JAD-180903. ISSN 1387-2877.
- ↑ Folstein MF, Folstein SE, McHugh PR (November 1975). ""Mini-mental state". A practical method for grading the cognitive state of patients for the clinician". J Psychiatr Res. 12 (3): 189–98. doi:10.1016/0022-3956(75)90026-6. PMID 1202204.
- ↑ Borson S, Scanlan JM, Chen P, Ganguli M (October 2003). "The Mini-Cog as a screen for dementia: validation in a population-based sample". J Am Geriatr Soc. 51 (10): 1451–4. doi:10.1046/j.1532-5415.2003.51465.x. PMID 14511167.
- ↑ Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (April 2005). "The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment". J Am Geriatr Soc. 53 (4): 695–9. doi:10.1111/j.1532-5415.2005.53221.x. PMID 15817019.
- ↑ Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H (2009). "A brief instrument to assess treatment response in the patient with advanced Alzheimer disease". Alzheimer Dis Assoc Disord. 23 (4): 377–83. doi:10.1097/WAD.0b013e3181ac9cc1. PMID 19571727.
- ↑ Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H (2009). "A brief instrument to assess treatment response in the patient with advanced Alzheimer disease". Alzheimer Dis Assoc Disord. 23 (4): 377–83. doi:10.1097/WAD.0b013e3181ac9cc1. PMID 19571727.
- ↑ Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000). "Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory". J Neuropsychiatry Clin Neurosci. 12 (2): 233–9. doi:10.1176/jnp.12.2.233. PMID 11001602.
- ↑ Cummings JL, Isaacson RS, Schmitt FA, Velting DM (March 2015). "A practical algorithm for managing Alzheimer's disease: what, when, and why?". Ann Clin Transl Neurol. 2 (3): 307–23. doi:10.1002/acn3.166. PMID 25815358.
- ↑ Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (May 2001). "Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 56 (9): 1143–53. doi:10.1212/wnl.56.9.1143. PMID 11342678.
- ↑ Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (May 2001). "Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 56 (9): 1133–42. doi:10.1212/wnl.56.9.1133. PMID 11342677.
- ↑ Squire LR, Zouzounis JA (December 1988). "Self-ratings of memory dysfunction: different findings in depression and amnesia". J Clin Exp Neuropsychol. 10 (6): 727–38. doi:10.1080/01688638808402810. PMID 3235647.
- ↑ Hack, Jason B.; Hoffman, Robert S. (1998). "Thiamine Before Glucose to Prevent Wernicke Encephalopathy: Examining the Conventional Wisdom". JAMA. 279 (8): 583. doi:10.1001/jama.279.8.583a. ISSN 0098-7484.